Metabolic side effects of antipsychotic drugs in the medium‑ to long‑term treatment of schizophrenia: a systematic review and network meta‑analysis
Funded by the German Ministry of Education and Research (BMBF, FKZ 01KG1904).
The project investigates how antipsychotics differ in their metabolic side effects during medium- to long-term treatment of schizophrenia.
Antipsychotics are a cornerstone of the treatment of schizophrenia and are used in both acute treatment and relapse prevention. Yet, it is not well known how antipsychotics differ in the medium- to long-term treatment of schizophrenia with respect to metabolic side effects. Metabolic side effects comprise weight gain and disturbances in lipid and glucose metabolism.
The method of network meta-analysis allows to estimate effect sizes for all possible drug comparisons, whether or not they were directly compared in a trial, providing a comprehensive review of all available evidence.
The systematic review and network meta-analysis protocol was pre-registered in Prospero under CRD42020175414 (see here), and published in BMC Systematic Reviews:
Schneider-Thoma, Johannes; Kapfhammer, Angelika; Wang, Dongfang; Bighelli, Irene; Siafis, Spyridon; Wu, Hui et al. (2021): Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials. In: Systematic reviews 10 (1), S. 214. DOI: 10.1186/s13643-021-01760-z.(Link)
Currently, the publication paper with the results of the network meta-analysis is in preparation.
Representatives of the association „BASTA - das Bündnis für psychisch erkrankte Menschen“ participate in the project.
The project was primarily conducted by Angelika Burschinski and Dr. Johannes Schneider-Thoma, contact: angelika.burschinski@tum.de
Supervision: Professor Stefan Leucht